Viracta Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch VIRX and buy or sell other stocks, ETFs, and their options commission-free!About VIRX
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.
CEOCraig R. Jalbert
CEOCraig R. Jalbert
Employees40
Employees40
HeadquartersCardiff, California
HeadquartersCardiff, California
Founded1998
Founded1998
Employees40
Employees40
VIRX Key Statistics
Market cap711.42K
Market cap711.42K
Price-Earnings ratio-0.02
Price-Earnings ratio-0.02
Dividend yield—
Dividend yield—
Average volume61.75K
Average volume61.75K
High today$0.0196
High today$0.0196
Low today$0.017
Low today$0.017
Open price$0.0176
Open price$0.0176
Volume8.18K
Volume8.18K
52 Week high$0.8201
52 Week high$0.8201
52 Week low$0.008
52 Week low$0.008
People also own
Based on the portfolios of people who own VIRX. This list is generated using Robinhood data, and it’s not a recommendation.